Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12421750 | 0.98 | CA12 (0.45) | CA12CA14CA1CA7CA2 | |
| SCHEMBL12792779 | 0.96 | CA12 (0.42) | CA12CA14CA1CA7CA2 | |
| SCHEMBL25670329 | 0.88 | KDM4E (0.39) | CA12CA14CA1CA7CA2 | |
| SCHEMBL3936868 | 0.86 | CA12 (0.41) | CA12CA14CA1CA7CA2 | |
| SCHEMBL4177994 | 0.85 | SMN1; SMN2 (0.47) | CA12CA14CA1CA7CA2 | |
| SCHEMBL17057869 | 0.85 | CA12 (0.40) | CA12CA14CA1CA7CA2 | |
| SCHEMBL13610628 | 0.83 | STS (0.47) | — | |
| SCHEMBL22404282 | 0.83 | CA12 (0.39) | CA12CA14CA1CA7CA2 | |
| SCHEMBL2801676 | 0.83 | CA12 (0.39) | CA12CA14CA1CA7CA2 | |
| SCHEMBL1371404 | 0.83 | CTSS (0.40) | CA12CA14CA1CA7CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024076872-A1 | HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE | TEON THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2023083343-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| EP-2624826-B1 | VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS | NOVARTIS AG (CH) | 2018-07-18 | — | — | EP | disclosed |
| CN-103179966-B | Vitamin E formulations of sulfonamide NS3 inhibitors | 诺瓦提斯公司 | 2017-03-15 | — | — | CN | disclosed |
| EP-2417108-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-9206232-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2015-12-08 | — | — | US | disclosed |
| US-9011833-B2 | Vitamin E formulations of sulfamide NS3 inhibitors | NOVARTIS AG (CH) | 2015-04-21 | — | — | US | disclosed |
| US-20140357551-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-8840878-B2 | Peptidomimetic sulfamide compounds and antiviral uses thereof | NOVARTIS AG (CH) | 2014-09-23 | — | — | US | disclosed |
| US-8613914-B2 | Peptidomimetic sulfamide compounds and antiviral uses thereof | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| WO-2007033175-A1 | INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | HTR3C, IDO1, HTR3B | CA12 4620/4885CA14 4430/4885CA1 4837/4885 |
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | CA12 4757/4885CA14 4424/4885CA1 4787/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | CA12 4757/4885CA14 4424/4885CA1 4787/4885 |
| US-20140357551-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | CA12 681/4885CA14 758/4885CA1 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.